-
Mashup Score: 0
An organization of retinal specialists flagged six cases of severe eye inflammation from commercial use of Syfovre. Apellis says the drug’s safety profile is consistent with testing.
Source: BioPharma DiveCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 3
New data presented Monday at a research conference support Lilly’s case for donanemab, while documenting its risks in greater detail.
Source: BioPharma DiveCategories: Latest Headlines, Rare DiseaseTweet-
RT @NedPagliarulo: Detailed data from $LLY help complete picture of Alzheimer's drug donanemab's benefit: https://t.co/RrbRbWVy4x from @re…
-
-
Mashup Score: 1
The agency granted a long-awaited clearance on Thursday, but unexpected aspects of the hemophilia treatment’s label had some investors worried about its commercial prospects.
Source: BioPharma DiveCategories: Latest Headlines, Rare DiseaseTweet-
RT @ABatemanHouse: With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy https://t.co/Jn2iFaC3Wu via @BioPharmaDive
-
-
Mashup Score: 2FDA approves new ALS medicine in precedent-setting decision - 11 month(s) ago
Biogen’s drug failed the key study meant to show it can slow the nerve-destroying disease, but the drug’s effect on a protein of interest led the FDA to conditionally clear it for market.
Source: BioPharma DiveCategories: Infectious Disease, Latest HeadlinesTweet-
FDA approves new ALS medicine in precedent-setting decision The drug, which will be sold as Qalsody, is only for the estimated 300 or so ALS patients in the U.S. who have a specific genetic mutation linked to the disease. https://t.co/0yPjN5KMad.
-
-
Mashup Score: 1Verve partners with Lilly on gene editing therapy for heart disease - 11 month(s) ago
Lilly will pay the genetic medicine specialist $60 million upfront to work together on a treatment targeting a risk factor known as Lp(a).
Source: BioPharma DiveCategories: Cardiologists, Latest HeadlinesTweet-
RT @NedPagliarulo: Verve partners with Lilly on gene editing therapy for heart disease https://t.co/yIHLeKsB58 $VERV $LLY
-
-
Mashup Score: 0Digital health funding holds steady in Q1 after year of decline - 11 month(s) ago
The sector defied trends seen in the larger venture capital environment, where funding continues to fall. But investment is still at years-low levels.
Source: BioPharma DiveCategories: Future of Medicine, Latest HeadlinesTweet-
Digital health funding holds steady in Q1 after year of decline https://t.co/Sqkl7cTym3 https://t.co/Y0JYTSlFTe
-
-
Mashup Score: 1J&J antibody drug combination shows promise in multiple myeloma - 11 month(s) ago
A pair of dual-acting antibodies displayed early potential to become a new type of drug regimen for the blood cancer, but led to a high rate of side effects as well.
Source: BioPharma DiveCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @NorthTxMSG: Tecvayli + Talquetamab show 84% ORR in a Phase 1 study to be presented at #ASCO23 @ASCO #mmsm https://t.co/JnMeWOrBzr via…
-
-
Mashup Score: 0
Imbruvica, long one of AbbVie’s top-selling medicines, has ceded market share in treating chronic lymphocytic leukemia to AstraZeneca’s Calquence.
Source: BioPharma DiveCategories: Hem/Oncs, Latest HeadlinesTweet-
@PallawiTorkaMD @jeff_sharman @RenoHemonc https://t.co/n01I1JExE3 1 billion sales a quarter is not bad !!!!
-
-
Mashup Score: 1Regeneron bets on ‘Treg’ cell therapy with Sonoma deal - 1 year(s) ago
The biotech will work with Sonoma, a well-funded startup run by prominent immunologist Jeffrey Bluestone, to develop cell-based medicines for ulcerative colitis and Crohn’s disease.
Source: BioPharma DiveCategories: Hem/Oncs, Latest HeadlinesTweet-
Fascinating. Will these approaches for non-malignant conditions be effective without lymphodepletion? What does the future hold? Regeneron bets on ‘Treg’ cell therapy with Sonoma deal https://t.co/zzK18yB80o via @BioPharmaDive
-
-
Mashup Score: 0
Weeks after the first Humira copycat launched in the U.S., a survey by Cardinal Health suggests insurer mandates will drive biosimilar adoption.
Source: BioPharma DiveCategories: Healthcare Professionals, Latest HeadlinesTweet-
Survey of 300 Rheums, GI, Derms - concerns w/ new biosimilars - majority say economics arent favorable to switch to biosimilar - Yet majority "very to somewhat” comfortable w/ biosimilars - US: Slow biosimilar uptake due to disappointing costs https://t.co/DOhrfELssY https://t.co/f2iy9igq5d
-
Apellis shares sink on reports of rare side effects with new vision loss drug https://t.co/v5n0U5LgsB via @BioPharmaDive